Go online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ultimately improve care for their patients with MM. Upon completion of this accredited CE activity, participants should be better able to: Summarize current evidence about the use of novel antibody platforms targeting CD38 and BCMA in relapsed/refractory multiple myeloma (RRMM), including in heavily pretreated disease, Integrate antibody-based therapies into team treatment plans for the management of patients with RRMM, Develop team-based strategies addressing practical aspects of antibody therapy in RRMM, including issues related to dosing/scheduling, unique safety considerations such as neutropenia, infection, and ocular toxicity, and patient and staff education on drug safety/delivery.

Podden och tillhörande omslagsbild på den här sidan tillhör PVI, PeerView Institute for Medical Education. Innehållet i podden är skapat av PVI, PeerView Institute for Medical Education och inte av, eller tillsammans med, Poddtoppen.